The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas
Open accessAbstract
The antitumor effect of doxorubicin (DOX) conjugated to a biodegradable dendrimer was evaluated in mice bearing C-26 colon carcinomas. An asymmetric biodegradable polyester dendrimer containing 8–10 wt % DOX was prepared. The design of the dendrimer carrier optimized blood circulation time through size and molecular architecture, drug loading through multiple attachment sites, solubility through PEGylation, and drug release through the use of pH-sensitive hydrazone linkages. In culture, dendrimer–DOX was >10 times less toxic than free DOX toward C-26 colon carcinoma cells after exposure for 72 h. Upon i.v. administration to BALB/c mice with s.c. C-26 tumors, dendrimer–DOX was eliminated from the serum with a half-life of 16 ± 1 h, and its tumor uptake was ninefold higher than i.v. administered free DOX at 48 h. In efficacy studies performed with BALB/c mice bearing s.c. C-26 tumors, a single i.v. injection of dendrimer–DOX at 20 mg/kg DOX equivalents 8 days after tumor implantation caused complete tumor regression and 100% survival of the mice over the 60-day experiment. No cures were achieved in tumor-implanted mice treated with free DOX at its maximum tolerated dose (6 mg/kg), drug-free dendrimer, or dendrimer–DOX in which the DOX was attached by means of a stable carbamate bond. The antitumor effect of dendrimer–DOX was similar to that of an equimolar dose of liposomal DOX (Doxil). The remarkable antitumor activity of dendrimer–DOX results from the ability of the dendrimer to favorably modulate the pharmacokinetics of attached DOX.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Block copolymer micelles for drug delivery: design, characterization and biological significance
Kataoka, K., Harada, A., & Nagasaki, Y. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00124-1 · Cited by 3,506
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Designing dendrimers for biological applications
Lee, C. C., MacKay, J. A., Fréchet, J. M. J., & Szoka, F. C. (2005) · Nature Biotechnology · doi:10.1038/nbt1171 · Cited by 2,043
Self-citationOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., & Redemann, C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11460 · Cited by 1,620
Dendrimers and dendritic polymers in drug delivery
Gillies, E. R., & Fréchet, J. M. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03276-3 · Cited by 1,367
Self-citationMalik, N., Wiwattanapatapee, R., Klopsch, R., Lorenz, K., Frey, H., Weener, J. W., Meijer, E. W., Paulus, W., & Duncan, R. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00246-1 · Cited by 1,227
(1996) · PubMed · Cited by 1,141
Kukowska-Latallo, J. F., Candido, K. A., Cao, Z., Nigavekar, S. S., Majoros, I. J., Thomas, T. P., Balogh, L. P., Khan, M. K., & Baker, J. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3921 · Cited by 912
Effective drug delivery by PEGylated drug conjugates
Greenwald, R. B., Choe, Y. H., McGuire, J., & Conover, C. D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00180-1 · Cited by 869
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Kataoka, K., Matsumoto, T., Yokoyama, M., Okano, T., Sakurai, Y., Fukushima, S., Okamoto, K., & Kwon, G. S. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00133-9 · Cited by 613
HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action
Kopecek, J. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00075-8 · Cited by 562
Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo
Maeda, H., Seymour, L. W., & Miyamoto, Y. (1992) · Bioconjugate Chemistry · doi:10.1021/bc00017a001 · Cited by 560
Polyester Dendritic Systems for Drug Delivery Applications: In Vitro and In Vivo Evaluation
Padilla De Jesús, O. L., Ihre, H. R., Gagne, L., Fréchet, J. M. J., & Szoka, F. C. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010103m · Cited by 507
Self-citationPolymeric anticancer drugs with pH-controlled activation
Ulbrich, K. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.040 · Cited by 494
Designing dendrimers for drug delivery
Liu, M., & Fréchet, J. M. J. (1999) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(99)00203-5 · Cited by 434
Self-citation(1991) · PubMed · Cited by 418
Dendrimer-platinate: a novel approach to cancer chemotherapy.
Malik, N., Evagorou, E. G., & Duncan, R. (1999) · PubMed · Cited by 417
Dendrimer-platinate: a novel approach to cancer chemotherapy
Malik, N., Evagorou, E. G., & Duncan, R. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199909000-00010 · Cited by 402
Polyester Dendritic Systems for Drug Delivery Applications: Design, Synthesis, and Characterization
Ihre, H. R., Padilla De Jesús, O. L., Szoka, & Fréchet, J. M. J. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010102u · Cited by 332
Self-citationGillies, E. R., & Fréchet, J. M. J. (2002) · Journal of the American Chemical Society · doi:10.1021/ja028100n · Cited by 328
Self-citationYokoyama, M. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00115-6 · Cited by 308
Fast and Convenient Divergent Synthesis of Aliphatic Ester Dendrimers by Anhydride Coupling
Ihre, H., Padilla De Jesús, O. L., & Fréchet, J. M. J. (2001) · Journal of the American Chemical Society · doi:10.1021/ja010524e · Cited by 296
Self-citationHuang, S. K., Mayhew, E. G., Gilani, S., Lasiç, D. D., Martin, F. J., & Papahadjopoulos, D. (1992) · PubMed · Cited by 274
Gillies, E. R., Dy, E., Fréchet, J. M. J., & Szoka, F. C. (2005) · Molecular Pharmaceutics · doi:10.1021/mp049886u · Cited by 265
Self-citationHPMA copolymers with pH-controlled release of doxorubicin
Ulbrich, K., Etrych, T., Chytil, P., Jelı́nková, M., & Řı́hová, B. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00348-6 · Cited by 198
Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin
Rihova, B., Bilej, M., Vetvicka, V., Ulbrich, K., Strohalm, J., Kopecek, J., & Duncan, R. (1989) · Biomaterials · doi:10.1016/0142-9612(89)90075-6 · Cited by 192
Seymour, L., Ulbrich, K., Steyger, P., Brereton, M., Subr, V, Strohalm, J., & Duncan, R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.363 · Cited by 164
Kaneko, T., Willner, D., Monkovic, I., Knipe, J. O., Braslawsky, G. R., Greenfield, R. S., & Vyas, D. M. (1991) · Bioconjugate Chemistry · doi:10.1021/bc00009a001 · Cited by 163
Dufès, C., Keith, W. N., Bilsland, A. E., Proutski, I., Uchegbu, I. F., & Schätzlein, A. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4402 · Cited by 146
The pharmacokinetics of polymer-bound adriamycin
Seymour, L. W., Ulbrich, K., Strohalm, J., Kopec̆ek, J., & Duncan, R. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90293-t · Cited by 122
Gabizon, A., Meshorer, A., & Barenholz, Y. (1986) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/77.2.459 · Cited by 114
Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin
Pechar, M., Ulbrich, K., Šubr, V., Seymour, L. W., & Schacht, E. H. (2000) · Bioconjugate Chemistry · doi:10.1021/bc990092l · Cited by 97
Soluble synthetic polymers in biological systems
Drobnik, J., & Rypáček, F. (1984) · Advances in polymer science · doi:10.1007/3-540-12796-8_9 · Cited by 65
Larwood, D. J., & Szoka, F. C. (1984) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2580210703 · Cited by 22
Self-citationSynthesis and biological properties of antitumor-active conjugates of ADR with dextran
Guu, J.-A., Hsiue, G., & Juang, T.-M. (2002) · Journal of Biomaterials Science Polymer Edition · doi:10.1163/156856202320813846 · Cited by 7
Cited by
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Nanoparticle-based targeted drug delivery
Singh, R., & Lillard, J. W. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.12.004 · Cited by 2,734
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Astruc, D., Boisselier, E., & Ornelas, C. (2010) · Chemical Reviews · doi:10.1021/cr900327d · Cited by 1,844
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Metadata
- Authors
- Lee, C. C., Gillies, E. R., Fox, M. E., Guillaudeu, S. J., Fréchet, J. M. J., Dy, E. E., & Szoka, F. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-11-07
- Volume
- 103
- Issue
- 45
- Pages
- 16649-16654
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2086626884
- Cited by
- 650
- References
- 41
- FWCI
- 30.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.